Immunexpress, Debiopharm, and Biocartis to Advance SeptiCyte Triage for Managing Sepsis
Summary
Immunexpress, Debiopharm, and Biocartis entered a worldwide, exclusive, royalty-bearing license for SeptiCyte® Triage for sepsis diagnosis and prognosis. Biocartis will subsequently fund the development and commercialization of the validated assay on its fully integrated molecular diagnostics platform. This platform, which includes an instrument, communication console, and single-use cartridges, can detect and quantify multiple DNA- or RNA-based biomarkers in a variety of patient sample types with minimal user intervention in less than 90 minutes, according to Biocartis. The Immunexpress SeptiCyte technology quantifies specific and multiple molecular markers from the patient’s own immune system for earlier detection, severity assessment, and better timing and targeting of drug and other therapies. By translating and quantifying complex molecular signals in an objective score, SeptiCyte provides reports on disease probabilities.